Comparing SG&A Expenses: Biogen Inc. vs Blueprint Medicines Corporation Trends and Insights

Biogen vs. Blueprint: SG&A Expense Trends Unveiled

__timestampBiogen Inc.Blueprint Medicines Corporation
Wednesday, January 1, 201422323420007890000
Thursday, January 1, 2015211310000014456000
Friday, January 1, 2016194790000019218000
Sunday, January 1, 2017193550000027986000
Monday, January 1, 2018210630000047928000
Tuesday, January 1, 2019237470000096388000
Wednesday, January 1, 20202504500000157743000
Friday, January 1, 20212674300000195293000
Saturday, January 1, 20222403600000237374000
Sunday, January 1, 20232549700000295141000
Monday, January 1, 20242403700000359272000
Loading chart...

Unleashing the power of data

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding financial trends is crucial. Over the past decade, Biogen Inc. and Blueprint Medicines Corporation have shown contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Biogen, a stalwart in the industry, has consistently maintained high SG&A expenses, peaking in 2021 with a 38% increase from 2014. In contrast, Blueprint Medicines, a rising star, has seen its SG&A expenses skyrocket by over 3,600% since 2014, reflecting its aggressive growth strategy. This divergence highlights the different stages and strategies of these companies. While Biogen focuses on sustaining its market position, Blueprint is investing heavily in expansion. These insights offer a glimpse into the strategic priorities shaping the biotech landscape today.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025